In $900M+ deal, rare disease biotechs team up on RNA therapies for CNS developmental disorders

Two biotechs that have built their reputations in rare disease research signed a new collaboration Monday morning aiming to develop three new RNA-based therapies. And the deal could be worth nearly $1 billion in biobucks if every milestone is met.

Acadia Pharmaceuticals and Stoke Therapeutics will team up on the...

Click to view original post